WEREWOLF THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
WEREWOLF THERAPEUTICS, INC. (HOWL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.10 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2023-11-14
- WEREWOLF THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-09-30 was $2.10M, a 8.32% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-06-30 was $1.93M, a 8.61% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-03-31 was $2.11M, a 20.80% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-09-30 was $1.94M, a 30.90% increase year-over-year.
- WEREWOLF THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $7.40M, a 80.71% increase from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $4.09M, a 547.94% increase from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $632.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.10M 10-Q · filed 2023-11-14 | $4.03M derived: sum of 2 quarters · filed 2023-11-14 | $6.13M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2023-06-30 | $1.93M 10-Q · filed 2023-11-14 | $4.04M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2023-03-31 | $2.11M 10-Q · filed 2023-11-14 | |||
| 2022-12-31 | $7.40M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $1.94M 10-Q · filed 2023-11-14 | $3.71M derived: sum of 2 quarters · filed 2023-11-14 | $5.46M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $1.78M 10-Q · filed 2023-11-14 | $3.52M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $1.75M 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $4.09M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $1.48M 10-Q · filed 2022-11-10 | $2.26M derived: sum of 2 quarters · filed 2022-11-10 | $2.80M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $781.00K 10-Q · filed 2022-11-10 | $1.32M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $539.00K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $632.00K 10-K · filed 2022-03-24 | |||
| 2020-09-30 | $133.00K 10-Q · filed 2021-11-10 | $354.00K derived: sum of 2 quarters · filed 2021-11-10 | $411.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $221.00K 10-Q · filed 2021-11-10 | $278.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $57.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |